Neurogene Reports Serious Adverse Event in Phase 1/2 Rett Study of Gene Therapy NGN-401

Published Date: 21 Nov 2024

The company has decided to pause enrollment in the high-dose cohort of its phase 1 clinical trial for NGN-401 after a participant experienced a serious treatment-related adverse event.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot